In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
Nanoparticulate drug delivery systems offer great promise in addressing challenges of drug toxicity, poor bioavailability and non-specificity for a number of drugs. Much progress has been reported for nano drug delivery systems for intravenous administration, however very little is known about the effects of orally administered nanoparticles. Furthermore, the development of nanoparticulate systems necessitates a thorough understanding of the biological response post exposure. This study aimed to elucidate the in vivo uptake of chitosan and polyethylene glycol (PEG) coated Poly, DL, lactic-co-glycolic Acid (PLGA) nanoparticles and the immunological response within 24 h of oral and peritoneal administration. These PLGA nanoparticles were administered orally and peritoneally to female Balb/C mice, they were taken up by macrophages of the peritoneum. When these particles were fluorescently labelled, intracellular localisation was observed. The expression of pro-inflammatory cytokines IL-2, IL-6, IL-12p70 and TNF-α in plasma and peritoneal lavage was found to remain at low concentration in PLGA nanoparticles treated mice as well as ZnO nanoparticles during the 24 hour period. However, these were significantly increased in lipopolysaccharide (LPS) treated mice. Of these pro-inflammatory cytokines, IL-6 and IL-12p70 were produced at the highest concentration in the positive control group. The anti-inflammatory cytokines IL-10 and chemokines INF-γ, IL-4, IL-5 remained at normal levels in PLGA treated mice. IL-10 and INF-γ were significantly increased in LPS treated mice. MCP-1 was found to be significantly produced in all groups in the first hours, except the saline treated mice. These results provide the first report to detail the induction of cytokine production by PLGA nanoparticles engineered for oral applications.
Semete
B
B
Council for Scientific and Industrial Research, Polymers and Composites, PO Box 395 Pretoria 0001, South Africa. Bsemete@csir.co.za
Booysen
L I J
LI
Kalombo
L
L
Venter
J D
JD
Katata
L
L
Ramalapa
B
B
Verschoor
J A
JA
Swai
H
H
D000284:Administration, Oral; D000818:Animals; D048271:Chitosan / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*; D016207:Cytokines / Q000096:biosynthesis; D016503:Drug Delivery Systems; D005260:Female; D019344:Lactic Acid / Q000276:immunology / Q000633:toxicity; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles; D010316:Particle Size; D011092:Polyethylene Glycols / Q000633:toxicity; D011100:Polyglycolic Acid / Q000633:toxicity; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
D016207:Cytokines; D008070:Lipopolysaccharides; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011092:Polyethylene Glycols; D048271:Chitosan